Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy VESPER-1 achieved a non-placebo-adjusted weight loss
TORONTO–(BUSINESS WIRE)–Kalloghlian Myers LLP is investigating a potential investor class action against TerraVest Industries Inc. (TSE: TVK). On June 5, 2026, TerraVest shares fell 31.6% following allegations that executive chairman Charles Pellerin tipped off family members and acquaintances ahead of
PALO ALTO, Calif.–(BUSINESS WIRE)–Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th Scientific Sessions. The company’s presentation slate focuses on the immediate utility
SAN DIEGO–(BUSINESS WIRE)–$PICS #Banking—Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired PicS N.V. (NASDAQ: PICS) securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection
STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts
